Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
CONCLUSION: NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment or substitution with other anti-COVID-19 agents such as molnupiravir.PMID:36592146 | DOI:10.47102/annals-acadmedsg.2022289 (Source: Ann Acad Med Singapo...)
Source: Ann Acad Med Singapo... - January 2, 2023 Category: General Medicine Authors: Kathleen Shu En Quah Xiaoling Huang Laurent Renia Hazel H Oon Source Type: research
Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature
(Source: European Journal of Dermatology)
Source: European Journal of Dermatology - January 1, 2023 Category: Dermatology Source Type: research
